TY - JOUR AU - Benjamin, K. AU - Vernon, M. K. AU - Patrick, D. L. AU - Perfetto, E. AU - Nestler-Parr, S. AU - Burke, L. PY - 2017 DA - 2017// TI - Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2017.05.015 DO - 10.1016/j.jval.2017.05.015 ID - Benjamin2017 ER - TY - JOUR AU - Cremers, S. AU - Aronson, J. K. PY - 2017 DA - 2017// TI - Drugs for rare disorders JO - Br J Clin Pharmacol VL - 83 UR - https://doi.org/10.1111/bcp.13331 DO - 10.1111/bcp.13331 ID - Cremers2017 ER - TY - JOUR AU - Cox, G. F. PY - 2018 DA - 2018// TI - The art and science of choosing efficacy endpoints for rare disease clinical trials JO - Am J Med Genet A VL - 176 UR - https://doi.org/10.1002/ajmg.a.38629 DO - 10.1002/ajmg.a.38629 ID - Cox2018 ER - TY - JOUR AU - Clarke, J. T. AU - Coyle, D. AU - Evans, G. AU - Martin, J. AU - Winquist, E. PY - 2014 DA - 2014// TI - Toward a functional definition of a "rare disease" for regulatory authorities and funding agencies JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.08.2672 DO - 10.1016/j.jval.2014.08.2672 ID - Clarke2014 ER - TY - JOUR AU - Gobburu, J. AU - Pastoor, D. PY - 2016 DA - 2016// TI - Drugs against rare diseases: are the regulatory standards higher? JO - Clin Pharmacol Ther VL - 100 UR - https://doi.org/10.1002/cpt.415 DO - 10.1002/cpt.415 ID - Gobburu2016 ER - TY - JOUR AU - Sasinowski, F. J. AU - Panico, E. B. AU - Valentine, J. E. PY - 2015 DA - 2015// TI - Quantum of effectiveness evidence in FDA's approval of orphan drugs: update, July 2010 to June 2014 JO - Ther Innov Regul Sci. VL - 49 ID - Sasinowski2015 ER - TY - JOUR AU - Djurisic, S. AU - Rath, A. AU - Gaber, S. AU - Garattini, S. AU - Bertele, V. AU - Ngwabyt, S. N. PY - 2017 DA - 2017// TI - Barriers to the conduct of randomised clinical trials within all disease areas JO - Trials VL - 18 UR - https://doi.org/10.1186/s13063-017-2099-9 DO - 10.1186/s13063-017-2099-9 ID - Djurisic2017 ER - TY - JOUR AU - Crow, R. A. AU - Hart, K. A. AU - McDermott, M. P. AU - Tawil, R. AU - Martens, W. B. AU - Herr, B. E. PY - 2018 DA - 2018// TI - A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial JO - Trials VL - 19 UR - https://doi.org/10.1186/s13063-018-2645-0 DO - 10.1186/s13063-018-2645-0 ID - Crow2018 ER - TY - JOUR AU - Kempf, L. AU - Goldsmith, J. C. AU - Temple, R. PY - 2018 DA - 2018// TI - Challenges of developing and conducting clinical trials in rare disorders JO - Am J Med Genet A VL - 176 UR - https://doi.org/10.1002/ajmg.a.38413 DO - 10.1002/ajmg.a.38413 ID - Kempf2018 ER - TY - JOUR AU - Jansen-van der Weide, M. C. AU - Gaasterland, C. M. W. AU - Roes, K. C. B. AU - Pontes, C. AU - Vives, R. AU - Sancho, A. PY - 2018 DA - 2018// TI - Rare disease registries: potential applications towards impact on development of new drug treatments JO - Orphanet J Rare Dis VL - 13 UR - https://doi.org/10.1186/s13023-018-0836-0 DO - 10.1186/s13023-018-0836-0 ID - Jansen-van der Weide2018 ER - TY - JOUR AU - Kakkis, E. D. AU - O'Donovan, M. AU - Cox, G. AU - Hayes, M. AU - Goodsaid, F. AU - Tandon, P. K. PY - 2015 DA - 2015// TI - Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints JO - Orphanet J Rare Dis. VL - 10 UR - https://doi.org/10.1186/s13023-014-0195-4 DO - 10.1186/s13023-014-0195-4 ID - Kakkis2015 ER - TY - JOUR AU - Nickel, M. AU - Simonati, A. AU - Jacoby, D. AU - Lezius, S. AU - Kilian, D. AU - Graaf, B. PY - 2018 DA - 2018// TI - Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study JO - Lancet Child Adolesc Health VL - 2 UR - https://doi.org/10.1016/S2352-4642(18)30179-2 DO - 10.1016/S2352-4642(18)30179-2 ID - Nickel2018 ER - TY - JOUR AU - Schulz, A. AU - Ajayi, T. AU - Specchio, N. AU - Los Reyes, E. AU - Gissen, P. AU - Ballon, D. PY - 2018 DA - 2018// TI - Study of intraventricular cerliponase alfa for CLN2 disease JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712649 DO - 10.1056/NEJMoa1712649 ID - Schulz2018 ER - TY - STD TI - International Conference on Harmonisation Expert Working Group. ICH Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials E10. 2000. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf. Accessed November 7, 2018. UR - https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf ID - ref14 ER - TY - JOUR AU - Manolis, E. AU - Pons, G. PY - 2009 DA - 2009// TI - Proposals for model-based paediatric medicinal development within the current European Union regulatory framework JO - Br J Clin Pharmacol VL - 68 UR - https://doi.org/10.1111/j.1365-2125.2009.03484.x DO - 10.1111/j.1365-2125.2009.03484.x ID - Manolis2009 ER - TY - STD TI - Yale University, Center for Outcomes Research and Evaluation. The YODA Project. http://yoda.yale.edu/. Accessed November 7, 2018. UR - http://yoda.yale.edu/ ID - ref16 ER - TY - STD TI - Cox G. Rare Disease Workshop Series: Section 2: Multivariate or Multiple Domain Methods. http://everylifefoundation.org/wp-content/uploads/images/workshopseries/AldurazymeResponderIndex-Cox.pdf. Acccessed November 26, 2018. UR - http://everylifefoundation.org/wp-content/uploads/images/workshopseries/AldurazymeResponderIndex-Cox.pdf ID - ref17 ER - TY - STD TI - Lee JJ. Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis [slide deck]. https://events-support.com/Documents/Lee.pdf. Accessed November 16, 2018.. UR - https://events-support.com/Documents/Lee.pdf ID - ref18 ER - TY - STD TI - Center for Drug Evaluation and Research. NDA 205494 Eliglustat Tartrate (Cerdelga) Clinical Pharmacology Review ADDENDUM. Application number: 205494Orig1s000. (Clinical Pharmacology and Biopharmaceutics Reviews). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000ClinPharmR.pdf. Accessed November 16, 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000ClinPharmR.pdf ID - ref19 ER - TY - JOUR AU - Signorovitch, J. AU - Ayyagari, R. AU - Kakkis, E. PY - 2014 DA - 2014// TI - The randomized blind start trial: evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.08.1963 DO - 10.1016/j.jval.2014.08.1963 ID - Signorovitch2014 ER - TY - STD TI - A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7). Available from: https://clinicaltrials.gov/ct2/show/NCT02230566. Accessed November 8, 2018. UR - https://clinicaltrials.gov/ct2/show/NCT02230566 ID - ref21 ER - TY - STD TI - Critical Path Institute. Advancing science through cross-disciplinary collaboration. https://c-path.org/about. Accessed November 7, 2018. UR - https://c-path.org/about ID - ref22 ER - TY - JOUR AU - Romero, K. AU - Sinha, V. AU - Allerheiligen, S. AU - Danhof, M. AU - Pinheiro, J. AU - Kruhlak, N. PY - 2014 DA - 2014// TI - Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-path-ISOP 2013 workshop JO - J Pharmacokinet Pharmacodyn VL - 41 UR - https://doi.org/10.1007/s10928-014-9390-0 DO - 10.1007/s10928-014-9390-0 ID - Romero2014 ER - TY - JOUR AU - McCormack, P. AU - Kole, A. AU - Gainotti, S. AU - Mascalzoni, D. AU - Molster, C. AU - Lochmuller, H. PY - 2016 DA - 2016// TI - 'You should at least ask.' the expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research JO - Eur J Hum Genet VL - 24 UR - https://doi.org/10.1038/ejhg.2016.30 DO - 10.1038/ejhg.2016.30 ID - McCormack2016 ER - TY - JOUR AU - Weber, K. AU - Hemmings, R. AU - Koch, A. PY - 2018 DA - 2018// TI - How to use prior knowledge and still give new data a chance? JO - Pharm Stat VL - 17 UR - https://doi.org/10.1002/pst.1862 DO - 10.1002/pst.1862 ID - Weber2018 ER - TY - JOUR AU - Kaddi, C. D. AU - Niesner, B. AU - Baek, R. AU - Jasper, P. AU - Pappas, J. AU - Tolsma, J. PY - 2018 DA - 2018// TI - Quantitative systems pharmacology modeling of acid sphingomyelinase deficiency and the enzyme replacement therapy Olipudase alfa is an innovative tool for linking pathophysiology and pharmacology JO - CPT Pharmacometrics Syst Pharmacol VL - 7 UR - https://doi.org/10.1002/psp4.12304 DO - 10.1002/psp4.12304 ID - Kaddi2018 ER - TY - JOUR AU - Thorlund, K. AU - Haggstrom, J. AU - Park, J. J. AU - Mills, E. J. PY - 2018 DA - 2018// TI - Key design considerations for adaptive clinical trials: a primer for clinicians JO - BMJ VL - 360 UR - https://doi.org/10.1136/bmj.k698 DO - 10.1136/bmj.k698 ID - Thorlund2018 ER - TY - JOUR AU - Hilgers, R. D. AU - Roes, K. AU - Stallard, N. PY - 2016 DA - 2016// TI - Directions for new developments on statistical design and analysis of small population group trials JO - Orphanet J Rare Dis. VL - 11 UR - https://doi.org/10.1186/s13023-016-0464-5 DO - 10.1186/s13023-016-0464-5 ID - Hilgers2016 ER - TY - STD TI - Center for Drug Evaluation and Research. E11(R1) Addendum: Clinical investigation of medicinal products in the pediatric population (Guidance for Industry). https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM530012.pdf. Published April 2018. Accessed November 16, 2018. UR - https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM530012.pdf ID - ref29 ER - TY - STD TI - Center for Drug Evaluation and Research. General clinical pharmacology considerations for pediatric studies for drugs and biological products (Guidance for Industry). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425885.pdf. Published December 2014. Accessed November 16, 2018. UR - http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425885.pdf ID - ref30 ER - TY - STD TI - European Medicines Agency. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. 7 October 2018. https://www.ema.europa.eu/documents/scientific-guideline/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf. Accessed November 7, 2018. UR - https://www.ema.europa.eu/documents/scientific-guideline/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf ID - ref31 ER - TY - JOUR AU - Dunne, J. AU - Rodriguez, W. J. AU - Murphy, M. D. AU - Beasley, B. N. AU - Burckart, G. J. AU - Filie, J. D. PY - 2011 DA - 2011// TI - Extrapolation of adult data and other data in pediatric drug-development programs JO - Pediatrics VL - 128 UR - https://doi.org/10.1542/peds.2010-3487 DO - 10.1542/peds.2010-3487 ID - Dunne2011 ER - TY - STD TI - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Final concept paper: Pediatric extrapolation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11A/E11A_ConceptPaper_Final_2017_1017.pdf. Published October 3, 2017. Accessed November 16, 2018. UR - http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11A/E11A_ConceptPaper_Final_2017_1017.pdf ID - ref33 ER - TY - JOUR AU - Sun, H. AU - Temeck, J. W. AU - Chambers, W. AU - Perkins, G. AU - Bonnel, R. AU - Murphy, D. PY - 2017 DA - 2017// TI - Extrapolation of efficacy in pediatric drug development and evidence-based medicine: progress and lessons learned JO - Ther Innov Regul Sci VL - 2017 ID - Sun2017 ER - TY - STD TI - Center for Drug Evaluation and Research. Developing targeted therapies in low-frequency molecular subsets of a disease. (Guidance for Industry). https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588884.pdf. Published October 2018. Accessed November 16, 2018. UR - https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588884.pdf ID - ref35 ER - TY - JOUR AU - Groft, S. C. AU - Posada de la Paz, M. PY - 2017 DA - 2017// TI - Rare diseases: joining mainstream research and treatment based on reliable epidemiological data JO - Adv Exp Med Biol VL - 1031 UR - https://doi.org/10.1007/978-3-319-67144-4_1 DO - 10.1007/978-3-319-67144-4_1 ID - Groft2017 ER - TY - STD TI - Center for Drug Evaluation and Research. Enrichment strategies for clinical trials to support approval of human drugs and biological products—Draft guidance. (Guidance for Industry). https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf. Published December 2012. Accessed November 16, 2018. UR - https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf ID - ref37 ER - TY - JOUR PY - 2018 DA - 2018// TI - Real-world evidence and real-world data for evaluating drug safety and effectiveness JO - JAMA VL - 320 UR - https://doi.org/10.1001/jama.2018.10136 DO - 10.1001/jama.2018.10136 ID - ref38 ER - TY - STD TI - Center for Biologics Evaluation and Research .Human gene therapy for rare diseases: Draft guidance for industry. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610802.pdf. Published July 2018. Accessed November 16, 2018. UR - https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610802.pdf ID - ref39 ER -